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Abstract
We describe the clinical Wndings, and the molecular and biochemical studies in an Italian family with recurrent hydrops fetalis due
to galactosialidosis (GS). GS is a rare lysosomal storage disorder caused by a deWciency of the protective protein/cathepsin A
(PPCA). This protein forms a high-molecular-weight complex with the hydrolases -galactosidase (GLB1) and neuraminidase
(NEU1). By virtue of this association these two enzymes are correctly compartmentalized in lysosomes and protected against rapid
proteolytic degradation. Controversial data show that PPCA is also present in a second complex, including the Elastin Binding Pro-
tein (EBP) the EBP-receptor, which is involved in elastogenesis, and NEU1. We investigated the potential role of the PPCA in both
complexes. Two new genetic lesions (c60delG and IVS2 + 1 G1T) that lead to a frameshift and a premature stop codon were
detected in the PPCA cDNA and genomic DNA of the patient. The deleterious eVect of such mutations was conWrmed by the com-
plete absence of the PPCA protein on Western blots. Thus, we examined the eVect of the loss of PPCA on the two protein complexes
in the patient’s Wbroblasts. Interestingly, a reduced amount of both GLB1 and EBP proteins was detected. These data conWrm that
PPCA is present in two functional complexes one with GLB1 and NEU1 in the lysosomal lumen and the other with EBP at the cell
surface. The reduction in GLB1 and EBP conWrms that PPCA is essential for their integrity.
 2004 Elsevier Inc. All rights reserved.
Keywords: Protective protein/cathepsin A; PPCA; PPBG gene; Lysosomal storage disease; Hydrops fetalis
Introduction ponding to the GLB1 protein and to the Elastin BindingGalactosialidosis (GS; McKusick 256540) is a rare
lysosomal storage disorder with an autosomal recessive
inheritance caused by a defect of in protective protein/
cathepsin A (PPCA). This protein forms a high-molecu-
lar-weight multicomplex with the hydrolases -galatosi-
dase (GLB1; E.C. 3.2.1.23) and neuraminidase (NEU1;
E.C. 3.2.1.18), defending them against rapid proteolytic
degradation and allowing them to take on the correct
folding [1]. The GLB1 gene, involved in GM1 gangliosi-
dosis, gives rise to two alternative spliced mRNAs corres-
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doi:10.1016/j.ymgme.2004.02.007Protein (EBP) [2,3]. A primary deWciency of the NEU1
gene gives rise to sialidosis. The PPCA deWciency leads
to a secondary combined deWciency of both GLB1 and
NEU1 proteins. PPCA is also required for transport of
NEU1 to lysosomes [4]. Besides protective function,
PPCA has a cathepsin A-like enzymatic activity at acid
pH and a deamidase/esterase activity at neutral pH [5].
PPCA plays an important role also in the EBP-receptor,
the major component of the non-integrin cell surface
receptor. The EBP-receptor is composed of three sub-
units: EBP, PPCA, and NEU1 [6,7]. In this complex,
EBP allows the secretion and assembly of tropoelastin
monomers into elastic Wbers, NEU1 attaches the complex
to the membrane surface, while PPCA carries out its
protective function of EBP and NEU1 [6–9].
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chromosome 20q13 [10], is organized into 14 exons and
one additional 30 untranslated region. The PPBG
mRNA contains 1815 nucleotides and encodes a 54 kDa
protein precursor which includes the N-terminus signal
sequence of 28 amino acids [11]. The signal peptide is
cleaved by proteases, producing the mature heterodimer
of 32 and 20 kDa chains [1,11]. These subunits are con-
nected by disulWde bridges. Based on the age of onset
and on the degree of clinical manifestations, GS has been
classiWed into early infantile form, late infantile form,
and juvenile/adult form [12]. Patients with early infantile
form show hydrops fetalis, hepatosplenomegaly, edema,
telangiectasias, and skeletal dysplasia. So far, only 18
mutations have been identiWed in the PPBG gene, most
of them in Japanese patients aVected by the juvanile/
adult form [13–20]. Determination of the atomic model
of PPCA [13] and characterization of mutations have
helped to clarify the molecular mechanism of wild type
and mutant PPCA proteins. Here we report clinical, bio-
chemical, and molecular studies of the second Italian
case of early infantile form of GS in a family with recur-
rent hydrops fetalis.
Family history
The patient was the second-born from unrelated Ital-
ian parent. The Wrst-born, a female, was delivered at the
31st week of pregnancy complicated by gestosis and
hydrops fetalis recognized by ultrasound at the 25th
week of gestation. She showed severe generalized
hydrops, sepsis, and disseminated intravascular coagula-
tion and died on the 16th day of age. Autopsy revealed
multiorgan dysfunction syndrome and congenital infec-
tion was suspected despite vacuolization of the liver.
The proband was delivered by cesarean section at the
26th week for ingravescent hydrops that was diagnosed
at the 18th week of gestation. The Apgar score was 2–3.
Immediately after birth he was intubated and resuscita-
tion procedures were instituted. Physical examination
showed hepatosplenomegaly, telangiectasias, and gener-
alized hydrops. During the Wrst day of his life evacuative
thoracentesis and abdominal paracentesis were neces-
sary. The patient’s clinical condition rapidly deteriorated
and mechanical ventilation was required. He died 52
days after birth. Since recurrent hydrops fetalis was pres-
ent in the history family and intrauterine infections or
iso-immunization were excluded, genetic and metabolic
investigations were performed. The karyotype was nor-
mal. Biochemical Wndings showed abnormal oligosac-
chariduria, vacuolated lymphocytes, abnormal pale
eosinophils with gray-greenish granules and neutrophils
with basophilic cytoplasmic granules in peripheral blood
smear. These data indicated a lysosomal storage disease.
Enzymatic assays of GLB1 and NEU1 showed thepatient’s cultured Wbroblasts has reduced activity while
his parents’ were normal (Table 1). The proband’s clini-
cal course and the laboratory Wndings allowed the diag-
nosis of the early infantile form of GS. Prenatal
diagnosis was performed in a third pregnancy by bio-
chemical and molecular analysis. The fetus resulted as a
normal female.
Materials and methods
Cell culture
Skin Wbroblasts from patient, his parents, and normal
controls were cultured in Ham’s F-10 medium supple-
mented with 10% fetal bovine serum and antibiotics.
Enzyme assays
Total protein concentration was determined in tripli-
cate by the Lowry method [21]. GLB1 and NEU1 enzy-
matic assays on Wbroblasts were performed in triplicate
as previously described [22] using artiWcial Xuorogenic
substrates (Koch-Light Laboratories, Colnbrook, UK).
PCR ampliWcation of genomic DNA
Genomic DNA was extracted from the patient’s
Wbroblasts and from his relatives’ peripheral blood lym-
phocytes using standard methods. The genomic frag-
ments covering all 14 exons and the exon/intron
boundaries of the PPBG gene were ampliWed by a set of
primers located in Xanking intronic sequences (Table 2).
PCR ampliWcation was performed under the following
conditions: initial denaturation at 94 °C for 4 min was
followed by 30 cycles with denaturation at 94 °C for 30 s,
annealing temperature of 63 °C for 30 s and extension at
72 °C for 1 min. All the ampliWcation reactions were per-
formed in a total volume of 25l containing 2.5 U Poly-
Taq DNA polymerase (Polymed, Sambuca-Firenze,
Italy), 25 mM of dNTPs, 200 ng forward primer, 200 ng
of the reverse primer, and 1£ PCR reaction buVer.
DNA sequencing
PCR fragments were separated on a 2% agarose gel
containing ethidium bromide and the bands were
Table 1
Enzymatic activities in Wbroblasts from the patient and from his
parents
Enzyme 
(nmol/mg/h)
Patient Mother Father n.v.
GLB1 79 510 344 300–525
NEU1 0 20 24 17–68
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were puriWed by Nucleospin Extract kit (Macherey-
Nagel, Düren, Germany), following the manufacturer’s
protocol. The double-stranded puriWed products were
used for direct sequencing with the same PCR ampliWca-
tion primers. The sequencing reactions were performed
by Big Dye Terminator Cycle Sequencing Ready Reac-
tion Kit reagents (Applied Biosystems, Foster City,
USA). The reactions were run on an ABI PRISM 310
sequencer and were analyzed using Sequencing analysis
software, version 3.3.
RNA isolation and synthesis of cDNA
Total RNA was extracted using a commercial kit,
(Perfect RNA Mini Eppendorf, Westbury, New York,
USA) and treated with RNase-free DNase. RNA integ-
rity was veriWed by 0.8% agarose gel electrophoresis, and
concentration was determined by OD 260. The full
length PPBG cDNA was directly synthesized, according
to the manufacturer’s instructions, using the Display
Thermo-RT Kit (Display Systems Biotech, Vista, CA,
USA) with an oligo-30dT primer. RT-PCR on the PPBG
cDNA was carried out by the following primer pairs 50-
CCAGTACTCCGGCTACCTCA (PPRNA1 sense) and
50-TGTTCCCCAGAAGGCCATGG (PPRNA6 anti-
sense) spanning the Wrst six exons. cDNA ampliWcation
was done under the following conditions: 1l of PPBG-
cDNA was added to 2.5 units of ampliTAQ DNA poly-
merase (Polymed, Sambuca-Firenze, Italy), 30 pmol of
both forward and reverse primers, and 1£ PCR reaction
buVer in a total volume of 25l. Cycling conditions were
the same as those used for genomic DNA ampliWcation.
The RT-PCR products were directly sequenced by auto-
matic DNA sequencer.
GeneScan analysis
A fragment containing the leucine-repeat region was
ampliWed using the forward Xuorescent primer (1–2 F)and the reverse normal primer (1R). One microlitre of
each PCR sample was mixed with 1l of the molecular
weight marker TAMRA-500 (Applied Biosystems, Fos-
ter City, USA) and 15l of deionized formamide. After
denaturation for 2 min at 95 °C, samples were chilled on
ice. The products were separated on POP-4 gel by an
ABI 310 Genetic Analyzer. The size determination was
calculated using the software GeneScan 3.1.
Western blot analysis
About 20g of total proteins from the patient’s Wbro-
blasts were used in the blots. Western blots were pre-
pared from 12.5% SDS–polyacrylamide gels and probed
as described [23]. Blots were developed with colorimetric
substrates [24]. Following electrophoresis, proteins were
transferred to nitrocellulose (Bio-Rad, Hercules, CA).
Western blot was carried out with: an anti-85 GLB1
antibody and anti-54 PPCA antibody [5,25], the anti-
EBP antibody provided by Igtech, (Perdifumo Savona,
Italy) and the anti-actin antibody (Sigma, Milano, Italy)
as control protein. The results of the blots were visual-
ized by reaction with the secondary antibody anti-rabbit
IgG (whole molecule) alkaline phosphatase conjugate
(Sigma, Milano, Italy), using the AP Conjugate Sub-
strate kit (Bio-Rad, Hercules, CA).
Immunostaining
Ten-day-old cultures from normal control’s and
patient’s Wbroblasts were Wxed at ¡20 °C in 100% metha-
nol for 30 min, as previously reported [2]. Each culture
was incubated separately for an hour with polyclonal
human tropoelastin (Elastin Products, Missouri, USA)
and Wbronectin (Sigma, Milano, Italy) antibodies, devel-
oped in rabbits. These cultures were incubated for an
additional hour with the secondary antibody anti-rabbit
Xuorescein isothiocyanate conjugated (Sigma, Milano,
Italy). Fibroblasts were incubated for 30 min with propi-
dium iodide (10g/ml) to stain nucleic acids.Table 2
PCR primers for genomic DNA ampliWcation and for sequencing analysis of the PPBG gene
Forward Reverse Fragment length (bp) N° exon
50-gaggcagcacgttcagctca 50-gaggagaaagagctgggctg 336 Signal sequence Ex 1
50-gaggaagactgtcacgtggc 50-gctgttgactcgctcctcag 268 Signal sequence Ex 2
50-ctgaggagcgagtcaacagc 50-cctcatccgtcatctcttctc 286 Ex 1
50-ctggaaagggcccctccaac 50-ctctgagaggtacaggcagc 314 Ex 2
50-ctctcatggtggccctttcc 50-tcatgccatggatggaggacc 341 Ex 3-4
50-gggtgggttaatgtcattatctc 50-taactgtaaggccacagcctc 301 Ex 5
50-gaaggtctgggtggtagggt 50-aggacagacctgagatcatgtg 235 Ex 6
50-cctcctctgccttcctcttc 50-gagggaatgtggtcctgttc 215 Ex 7
50-caacttggtggggtcgtggag 50-ccacctcaccaggaggaagc 353 Ex 8–9
50-cagggaagcagaggccctga 50-aagccccagcaacccaccac 231 Ex 10
50-gagagaaggtctgatctgttga 50-cttgtcctgacaggaagtctc 247 Ex 11
50-gactgggcttgttccacacc 50-tgggtcctgctcctttgcctc 496 Ex 12–13
50-ctgggaagaataaagggtttgg 50-gggcactttgcttagaagagg 273 Ex 14
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Sequencing analysis of the PPGB gene
Mutation analysis was performed by direct sequenc-
ing of all the 14 exons and the intron/exon boundaries of
the patient’s PPBG gene. The patient resulted as a com-
pound heterozygote for two new genetic lesions. The Wrst
mutation, present in the paternal allele, was IVS2 + 1
G1T, which alters the highly conserved splice donor
consensus site (Fig. 1B). AmpliWcation of the patient’s
cDNA by the exonic primers PPRNA1 and PPRNA6
revealed an additional band of 436 bp besides the normal
548 bp product. The shorter fragment was sequenced
and was found to be missing an exon 2 (Fig. 2). The skip-
ping of this exon results in an out-of-frame deletion, giv-
ing rise to a premature stop codon. In addition, the new
polymorphism L102L was identiWed in the patient’s and
in his father’s genomic DNAs. This polymorphic site is
located in exon 2 (c306G1A) close to the IVS2 + 1
G1T mutation (Fig. 1B). The second mutation, inher-
Fig. 1. Partial nucleotide sequence of the PPBG gene. Genomic DNA
isolated from the patient’s Wbroblasts was ampliWed by PCR. (A) In
exon 1 of the patient’s PPBG gene, the new c60delG genetic lesion was
identiWed at the heterozygous level. A normal control is shown lower.
(B) The Wrst base of intron 2 (IVS2 + 1 G1T), which alters the highly
conserved splice donor consensus site, was mutated in the patient’s
DNA. The splice donor site in the control sequence (lower) is boxed.
Moreover, the last nucleotide of exon 2 c306G1A was a polymorphic
site which is adjacent to the IVS2 + 1 G1T mutation (panel B).ited from his mother, was a single base deletion in exon 1
(c60delG), leading to a premature stop codon within 273
bases (Fig. 1A). In his mother’s and maternal grandfa-
ther’s DNAs a deletion of a leucine in the nine-leucine-
repeat region was also detected at heterozygous level,
while in his father’s DNA both alleles had eight leucines.
The single leucine-deletion was in exon 1 of the PPBG
gene, a few bases upstream of the c60delG genetic lesion.
In order to investigate the benign nature of this muta-
tion, 200 chromosomes from unaVected Italian individu-
als were analyzed by GeneScan. The leucine repeat
region in exon 1 was highly polymorphic with a fre-
quency of nine repeats in 34.5% of the population, eight
repeats in 38.5%, and ten repeats in 1% (Fig. 4).
Western blotting
Western blot analysis revealed the absence of the
PPCA mature form in the lane corresponding to the
patient’s Wbroblasts. Western blots using GLB1 and
EBP antibodies showed a decreased amount of both
GLB1 and EBP proteins in the patient’s Wbroblasts com-
pared to the control lane. The anti-actin antibody was
used in order to check the amounts of loaded proteins
(Figs. 3A–C).
Immunostaining
Immunostaining with anti-tropoelastin in normal
Wbroblasts showed the long elastic Wbers forming a con-
tinuos net in comparison with the patient’s Wbroblasts
where no deposition of organized elastin Wbers was pres-
ent (Fig. 5). The parallel cultures immunostained with
anti-Wbronectin antibody showed the patient’s Wbro-
blasts deposit more Wbronectin than the control’s
(Fig. 5). This eVect seems to be due to the failure of the
EBP to inhibit the stimulation of Wbronectin synthesis,
as previously reported [2,26].
Discussion
Our patient was a typical case of early infantile form
of GS. Clinical Wndings such as hydrops fetalis, severe
generalized edema at birth, hepatosplenomegaly, telangi-
ectasias, vacuoles in peripheral blood lymphocytes, and
oligosacchariduria, led us to suspect a lysosomal storage
disorder. In particular, a blood smear with eosinophils
displaying unusually pale cytoplasm with coarse and
gray-greenish stained granules indicated GM1 gangliosi-
dosis, sialidosis or galactosialidosis [27].
The characteristics of this case are represented by
recurrent hydrops fetalis in two subsequently pregnan-
cies and by the identiWcation of two new severe genetic
lesions. Hydrops fetalis may be an extreme presentation
of several lysosomal storage disorders as well as other
52 S. Malvagia et al. / Molecular Genetics and Metabolism 82 (2004) 48–55actin protein shows equal intensity in all lanes.Fig. 2. Sequencing analysis of the PPBG cDNA. RT-PCR products obtained from the total RNA and spanning exon 1–3 showed an aberrant splicing
lacking exon 2 in the patient’s Wbroblasts (B) that was absent in the Wbroblasts from the control (A).Fig. 3. Western blotting of PPCA, EBP, and GLB1. Fibroblasts from the patient and from a normal control were lysates and total proteins were
separated by SDS–PAGE. (A) The nitrocellular Wlter was incubated with the 54 anti PPCA and the anti-actin antibodies as control protein
(42 kDa). In the control lane two bands corresponding of the precursor form of PPCA (54 kDa) and of actin (42 kDa) are present. In the patient no
band of 54 kDa molecular weight has been identiWed, in agreement with genetic lesions found. (B,C) The Western blot using anti-GLB1 and anti-EBP
antibodies demonstrates a decreased amount of both GLB1 and EBP proteins in the patient’s Wbroblasts, compared to the control lane. The control
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ease, LCHAD defect, and Greenberg skeletal dysplasia
[28,29]. On the other hand, lysosomal storage disorders
represent 1–2% of the non-immune hydrops fetalis [30].
All patients aVected by the early infantile form of galac-
tosialidosis present hydrops fetalis, but only two families
with recurrent hydrops fetalis were reported in the
Fig. 4. GeneScan analysis of the frequency in the Italian population
of polymorphisms in the rich-leucine region of the PPBG gene. Gene-
Scan analysis showed a double peak, corresponding to a 281 bp and a
284 bp fragment in 48% of samples (A); only the Wrst peak of 281 bp
(B) appeared in 21%; a double peak of 281 bp and 287 bp in 2% (C);
only the second peak of 284 bp (D) in 29%. The frequency was based
on the analysis of 200 control chromosomes. Sequencing analysis
revealed that samples with double peaks of 281 and 284 bp were het-
erozygotes for the one leucine deletion, samples with double peaks of
281 and 287 bp had a leucine insertion in one allele and a leucine dele-
tion in the other allele, samples with the 281 peak were lacking a leu-
cine at the homozygous level and samples with the 184 peak were
normal.literature and none of them have been characterized at a
molecular level [12].
The severe clinical Wndings of our patient are strictly
correlated with his serious PPBG genetic lesions. Molec-
ular analysis of the patient’s and of his parents’ DNA
identiWed the two new PPBG genetic lesions: c60delG
and IVS2 + 1 G1T.
The c60delG, which leads to an out reading frame
and to a premature stop codon after 273 bases, with the
c517delTT are the only deletions reported in the PPGB
gene [16]. The other mutation is the IVS2 + 1 G1T
splicing defect, which causes the skipping of exon 2 and
introduces a premature stop codon. Two other abnormal
splicing mutations are in the PPBG gene have been
reported previously (IVS7 + 3 A1G, IVS8 + 9 C1G).
The mutation in the 50 splicing donor site of intron 7
(IVS7 + 3 A1G) has been described as a common
mutation in Japanese patients, [17]. This mutation at the
homozygous state correlates with a relatively mild juve-
nile/adult phenotype related to a residual normal
mRNA. In compound heterozygosity with missense
mutations, IVS7 + 3 A1G was correlated with more
severe clinical presentation [12,20]. The other previously
reported intronic mutation (IVS8 + 9 C1G) was identi-
Wed in a late infantile Caucasian patient with a deletion
of two nucleotides (c517delTT). The small amount of
PPCA detected in the Wbroblasts of this patient suggests
that a few mRNA molecules were normally spliced [18].
On the other hand, immunoblot analysis revealed that
no residual PPCA protein was present in our patient’s
Wbroblasts. The onset and severity of the symptoms in
GS patients correlate closely with the amount of residual
PPCA in lysosomes [19]. Thus, the complete absence of
PPCA protein in our patient explains his severe clinical
condition with exitus at 52 days of age.
A molecular prenatal diagnosis for a third pregnancy
was carried out on a chorionic villi sample. Direct
sequencing of fetal DNA identiWed no paternal or
maternal genetic lesions. In addition, the fetus resulted
to be homozygous for the deletion of one leucine (eight
instead of nine). Since the maternal c60delG mutation
was inherited from his grandmother who had both
alleles with nine leucine, the mutant maternal allele had
nine leucine while the other maternal allele with eight
leucine was normal. These data conWrmed that the fetus
inherited a normal allele from his mother.
In order to check the eVect of mutant PPCA in the
lysosomal complex and also in the EBP-receptor, the
immunoblots with anti-GLB1 and anti-EBP antibodies
were performed. Interestingly, the Western blot analysis
revealed, in the patient’s Wbroblasts compared to the
normal control, a reduced amount of both GLB1 and
EBP proteins. These data conWrm that PPCA is present
in two functional complexes inside lysosomes with
GLB1 and on the cell surface with EBP. Impaired elasto-
genesis due to the disruption of EBP function has been
54 S. Malvagia et al. / Molecular Genetics and Metabolism 82 (2004) 48–55reported in Costello, Morquio B syndrome, and Hurler
disease [31,32].
In order to determinate more precisely the functional
role of PPCA in the elastin binding protein, immuno-
staining experiment was performed. The cell cultures
treated with anti-elastin and anti-Wbronectin antibodies
showed the existence of impaired elastogenesis in the
patient’s Wbroblasts. These data conWrm that PPCA is
essential for GLB1 and EBP integrity and suggest that
some of the clinical manifestations of lysosomal disor-
ders such as skeletal deformities, loose skin, ligamentous
laxity, and heart involvement could be caused by
impaired elastogenesis [30]. We hypothesized that skele-
tal deformities and ligamentous laxity found in our
patient could be linked to a secondary defect of EBP
caused by the loss of the protective function of PPCA.
Cardiac involvement, frequently reported in GS patients
[12,33], was probably not observed in the proband
because of his short life span (52 days).
The knowledge that some metabolic inherited dis-
eases are responsible for hydrops fetalis can assist in the
diagnosis of cases where an immunological cause is
excluded. In families at high risk of recurrent hydropsfetalis it is important to make the diagnosis early in
order to provide genetic counseling.
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